.gif)
Oaktree Acquisition Corp. III Life Sciences
37
No recent news or business-impacting developments were reported.
Oaktree Acquisition Corp. III Life Sciences operates as a special purpose acquisition company (SPAC) targeting the life sciences sector. As a SPAC, its primary business model involves raising capital through an initial public offering to acquire or merge with an existing company in the life sciences industry. The company’s financial disclosures are limited, with no reported revenue or detailed operational data. The latest SEC filings provide insight into its liquidity position and net income for the recent quarter ending June 30, 2026.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Oaktree Acquisition Corp. III Life Sciences is a SPAC focused on life sciences with limited disclosed operational details. The latest SEC 10-Q filing dated August 12, 2026, reports cash and cash equivalents of approximately $1.18 million, current assets of about $1.26 million, current liabilities of approximately $1.73 million, and net income of about $1.6 million for the quarter ended June 30, 2026. Liquidity ratios indicate current ratio of 0.73 and cash ratio of 0.68, reflecting liquidity below 1. No revenue or EPS data are disclosed.
The company’s net income and liquidity position as reported in recent SEC filings suggest some financial stability. Its focus on the life sciences sector may provide access to high-growth opportunities through a successful business combination. The SPAC structure allows flexibility in pursuing acquisitions that could create shareholder value if executed effectively.
Limited disclosure of operational details and absence of revenue data reduce transparency into the company’s business model and prospects. Liquidity ratios below 1 indicate potential short-term liquidity constraints. The success of the company is contingent on completing a suitable acquisition, which carries execution risk and uncertainty inherent to SPACs.
As a SPAC, Oaktree Acquisition Corp. III Life Sciences does not have a traditional competitive moat based on proprietary products or services. Its value proposition lies in its ability to identify and complete a business combination with a promising life sciences company. The company’s moat depends on the management team's expertise and access to attractive acquisition targets within the life sciences sector.
• Liquidity Risk: Current ratio of 0.73 and cash ratio of 0.68 as of June 30, 2026, indicate liquidity below 1, which may constrain the company’s ability to meet short-term obligations.
• Execution Risk: As a SPAC, the company’s value depends on successfully identifying and completing a business combination in the life sciences sector, which involves significant uncertainty and timing risk.
• Limited Disclosure: The company provides minimal operational and financial details beyond liquidity and net income, limiting visibility into its business model and financial health.
Business trends: The company remains focused on completing a business combination in the life sciences sector, with financial data indicating liquidity below 1 and positive net income.
Execution milestones: Key milestones include identifying and closing a suitable acquisition target and improving liquidity metrics.
Key risks: Execution risk in completing a business combination, liquidity constraints, and limited transparency into operational details.
Low visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Oaktree Acquisition Corp. III Life Sciences is a special purpose acquisition company (SPAC) focused on the life sciences sector.
- As of June 30, 2026, the company reported cash and cash equivalents of $1,179,670 and current assets of $1,259,928.
- Current liabilities as of June 30, 2026, were $1,729,833, resulting in a current ratio of 0.73 and a cash ratio of 0.68, indicating liquidity below 1.
- The company reported net income of $1,604,621 for the quarter ending June 30, 2026.
- No revenue or earnings per share data were disclosed in the latest SEC filings.
- The latest financial data is from the 10-Q filed on August 12, 2026, covering the quarter ended June 30, 2026.
- The company does not disclose detailed operational or business model information in the available filings.
- The company’s financial figures are summarized from SEC filings and provided for informational purposes only.
Generated 2026-08-13
- S1 | 2026-03-26 | 10-K
- S2 | 2026-08-12 | 10-Q
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.
Generated by Valye SEC Pipeline Engine